what’s in the works
Our lead candidate, CBX-11, leverages the FDA- and EMA-approved PARP inhibitor rucaparib and is being developed as an intravenous formulation. It is being administered in combination with temozolomide (TMZ) and/or other DNA-damaging agents. Phase I is expected to begin 1Q20.
Licensing discussions are ongoing to expand the Cybrexa portfolio with additional development candidates.
initial development focus
Mediated by proteins such as PARP, ATM, ATR, and DNA-PK, DNA damage response (DDR) pathways detect and repair errors in the genome. DDR inhibitor therapies induce cancer cell death by straining an already deficient repair response. However, DDR inhibitor therapy does not work well outside of DDR deficient cancer types. Approximately 40-50% of all cancer patients are thought to have DDR deficient tumors, although many of the relevant mutations have not yet been characterized.
By enhancing the therapeutic index and enabling combination therapies that were previously limited by their toxicity, alphalex allows expansion into DDR proficient cancer types.
2019 global sales potential
